Dual incretin agonist: difference between revisions
Diff·revision 24 → 25·01:17, 30 Aug 2025
Difference between revision 24 and revision 25 of Dual incretin agonist. 3 lines changed; the page grew by 485 bytes.
| Revision 24 — 14:31, 5 Aug 2025 CategoryBot (talk) bot: repair redlinked category 5,366 bytes ±0 | Revision 25 — 01:17, 30 Aug 2025 CuriousCallum (talk) label the animal data as animal data in the sentence, not only in the section heading 5,851 bytes +485 | ||
|---|---|---|---|
| 37 | Amylin/GLP-1 pairing is achieved differently: [[CagriSema|CagriSema]] is a co-formulation of two separate peptides rather than one molecule, which reintroduces the possibility of differential pharmacokinetics but allows the ratio to be chosen at formulation. | 37 | Amylin/GLP-1 pairing is achieved differently: [[CagriSema|CagriSema]] is a co-formulation of two separate peptides rather than one molecule, which reintroduces the possibility of differential pharmacokinetics but allows the ratio to be chosen at formulation. |
| 38 | 38 | ||
| + | 39 | Adding a third receptor gives the [[Triple agonist|triple agonists]], of which [[Retatrutide|retatrutide]] is the most advanced. Each additional receptor multiplies the design constraints, and the tolerability window narrows as more pathways are engaged simultaneously.{{r|finan2013,campbell2013}} | |
| + | 40 | ||
| 39 | == References == | 41 | == References == |
| 40 | {{reflist}} | 42 | {{reflist}} |
| ⋮ | ⋮ | ||
| 42 | <ref name="coskun2018">Coskun T, Sloop KW, Loghin C, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus." ''Molecular Metabolism'' 18:3–14 (2018). PMID 30473097.</ref> | 44 | <ref name="coskun2018">Coskun T, Sloop KW, Loghin C, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus." ''Molecular Metabolism'' 18:3–14 (2018). PMID 30473097.</ref> |
| 43 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). PMID 34170647.</ref> | 45 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). PMID 34170647.</ref> |
| + | 46 | <ref name="campbell2013">Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). PMID 23684623.</ref> | |
| 44 | 47 | ||
| 45 | == See also == | 48 | == See also == |